Halozyme Therapeutics Raises 2026 Earnings Guidance Following Strong Q3 Performance
Halozyme Therapeutics (HALO) has reported strong third-quarter results, driven by the increasing adoption of its ENHANZE subcutaneous delivery technology. The company's management noted growing demand from physicians and healthcare systems as more patients transition to subcutaneous administration methods. Following these results, Halozyme raised its full-year 2026 non-GAAP earnings per share (EPS) guidance to a range of $8.75–$9.05. Additionally, the company projects 2026 revenue to fall between $1.86 billion and $1.925 billion, reflecting positive momentum in its core technology platform.
Tickers: $HALO
Topics: earnings report ENHANZE technology subcutaneous delivery